Cytospire
0 followers
About Cytospire
Cytospire Therapeutics develops next-generation immune cell engagers, focusing on multispecific antibodies designed to direct and enhance the activity of innate and adaptive immune cells. The company aims to provide a safer, tailored alternative to CD3-based engagers and is advancing a portfolio of therapies with potential applications in cancer immunotherapy. Operations appear to be based in the United Kingdom, led by a management team and supported by investors. The site emphasizes its multispecific antibody approach to reprogram immune responses for therapeutic benefit.